Immunoproteomics: Mass spectrometry-based methods to study the targets of the immune response.

The mammalian immune system has evolved to display fragments of protein antigens derived from microbial pathogens to immune effector cells. These fragments are typically peptides liberated from the intact antigens through distinct proteolytic mechanisms that are subsequently transported to the cell surface bound to chaperone-like receptors known as major histocompatibility complex (MHC) molecules. These complexes are then scrutinized by effector T cells that express clonally distributed T cell receptors with specificity for specific MHC-peptide complexes. In normal uninfected cells, this process of antigen processing and presentation occurs continuously, with the resultant array of self-antigen-derived peptides displayed on the surface of these cells. Changes in this peptide landscape of cells act to alert immune effector cells to changes in the intracellular environment that may be associated with infection, malignant transformation, or other abnormal cellular processes, resulting in a cascade of events that result in their elimination. Because peptides play such a crucial role in informing the immune system of infection with viral or microbial pathogens and the transformation of cells in malignancy, the tools of proteomics, in particular mass spectrometry, are ideally suited to study these immune responses at a molecular level. Here we review recent advances in the studies of immune responses that have utilized mass spectrometry and associated technologies, with specific examples from collaboration between our laboratories.

[1]  A. D. De Groot,et al.  Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. , 1998, Vaccine.

[2]  M. Mann,et al.  Analysis of proteins and proteomes by mass spectrometry. , 2001, Annual review of biochemistry.

[3]  Jonathan W. Yewdell,et al.  Immunoproteasomes Shape Immunodominance Hierarchies of Antiviral Cd8+ T Cells at the Levels of T Cell Repertoire and Presentation of Viral Antigens , 2001, The Journal of experimental medicine.

[4]  J. Vollmer,et al.  Cross‐reactive trinitrophenylated peptides as antigens for class II major histocompatibility complex‐restricted T cells and inducers of contact sensitivity in mice. Limited T cell receptor repertoire , 1995, European journal of immunology.

[5]  J. Shabanowitz,et al.  Specific recognition of thymic self-peptides induces the positive selection of cytotoxic T lymphocytes. , 1997, Immunity.

[6]  D. Wiley,et al.  Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1 , 1993, Nature.

[7]  A. Sette,et al.  Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. , 2003, Current opinion in immunology.

[8]  S. Gygi,et al.  Mass spectrometry and proteomics. , 2000, Current opinion in chemical biology.

[9]  H. Rammensee,et al.  Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast , 1991, The Journal of experimental medicine.

[10]  J. McCluskey,et al.  CTL recognition of an altered peptide associated with asparagine bond rearrangement. Implications for immunity and vaccine design. , 1996, Journal of immunology.

[11]  A. Purcell,et al.  The peptide-loading complex and ligand selection during the assembly of HLA class I molecules. , 2000, Molecular immunology.

[12]  G. Pesole,et al.  Compositional bias and mimicry toward the nonself proteome in immunodominant T cell epitopes of self and nonself antigens , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  S. Zolla-Pazner,et al.  Mass Spectrometric Characterization of a Discontinuous Epitope of the HIV Envelope Protein HIV-gp120 Recognized by the Human Monoclonal Antibody 1331A1 , 2000, The Journal of Immunology.

[14]  Sarah M Weenink,et al.  Antigen presentation by MHC class II molecules , 1997, Immunology and cell biology.

[15]  J. Shabanowitz,et al.  Susceptibility to ankylosing spondylitis correlates with the C‐terminal residue of peptides presented by various HLA‐B27 subtypes , 1997, European journal of immunology.

[16]  D. Hunt,et al.  Direct analysis of tumor-associated peptide antigens. , 1994, Current opinion in immunology.

[17]  Nan Hu,et al.  2D Differential In-gel Electrophoresis for the Identification of Esophageal Scans Cell Cancer-specific Protein Markers* , 2002, Molecular & Cellular Proteomics.

[18]  M. Garcia-Peydró,et al.  Quantitative and Qualitative Influences of Tapasin on the Class I Peptide Repertoire1 , 2001, The Journal of Immunology.

[19]  D. Hunt,et al.  Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68. , 1994, Cancer research.

[20]  N. Pavletich,et al.  Structure of the p53 Tumor Suppressor Bound to the Ankyrin and SH3 Domains of 53BP2 , 1996, Science.

[21]  K. Ballingall,et al.  The DY sub-region of the sheep MHC contains an A/B gene pair , 2004, Immunogenetics.

[22]  J. Lieberman,et al.  Prediction of HIV peptide epitopes by a novel algorithm. , 1996, AIDS research and human retroviruses.

[23]  L. Beretta,et al.  Proteomic-Based Approach for the Identification of Tumor Markers Associated with Hepatocellular Carcinoma , 2002, Disease markers.

[24]  P. Kloetzel,et al.  The effect of the interferon‐γ‐inducible processing machinery on the generation of a naturally tumor‐associated human cytotoxic T lymphocyte epitope within a wild‐type and mutant p53 sequence context , 2002, European journal of immunology.

[25]  J. Shabanowitz,et al.  Identification of endogenous peptides recognized by in vivo or in vitro generated alloreactive cytotoxic T lymphocytes: distinct characteristics correlated with CD8 dependence , 2001, European journal of immunology.

[26]  E. Padlan,et al.  Analysis of the structure of naturally processed peptides bound by class I and class II major histocompatibility complex molecules. , 1995, EXS.

[27]  J. Villadangos,et al.  Presentation of antigens by MHC class II molecules: getting the most out of them. , 2001, Molecular immunology.

[28]  K. Parker,et al.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.

[29]  R. Henderson,et al.  Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. , 1994, Science.

[30]  T. Elliott,et al.  Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. , 1999, Journal of immunology.

[31]  E. Petricoin,et al.  New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics. , 2001, Urology.

[32]  M. Boyle,et al.  Application of immunoproteomics to analysis of post‐translational processing of the antiphagocytic M protein of Streptococcus , 2003, Proteomics.

[33]  K. Williams,et al.  Proteomic analysis of immunostained, laser‐capture microdissected brain samples , 2003, Electrophoresis.

[34]  M. Stanford,et al.  Delineation of Five Thyroglobulin T Cell Epitopes with Pathogenic Potential in Experimental Autoimmune Thyroiditis1 , 2002, The Journal of Immunology.

[35]  E. Celis,et al.  Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes. , 2000, Cancer research.

[36]  H. Rammensee,et al.  Peptides naturally presented by MHC class I molecules. , 1993, Annual review of immunology.

[37]  J. Berzofsky,et al.  Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences. , 1995, Vaccine.

[38]  P. Matzinger Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[39]  J. Shabanowitz,et al.  Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. , 1998, Journal of immunology.

[40]  J. McCluskey,et al.  Novel strategy for identification of candidate cytotoxic T-cell epitopes from human preproinsulin. , 2003, Tissue antigens.

[41]  J. Shabanowitz,et al.  Differences in the Expression of Human Class I MHC Alleles and Their Associated Peptides in the Presence of Proteasome Inhibitors1 , 2001, The Journal of Immunology.

[42]  J. Yewdell,et al.  MHC-encoded proteasome subunits LMP2 and LMP7 are not required for efficient antigen presentation. , 1994, Journal of immunology.

[43]  P. Cresswell,et al.  Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. , 1996, Immunity.

[44]  J. McCluskey,et al.  Tapasin-Mediated Retention and Optimization of Peptide Ligands During the Assembly of Class I Molecules1 , 2000, The Journal of Immunology.

[45]  S. Nathenson,et al.  Methods to study peptides associated with MHC class I molecules. , 1994, Current opinion in immunology.

[46]  Forest M White,et al.  Analysis of MHC Class II Antigen Processing by Quantitation of Peptides that Constitute Nested Sets , 2002, The Journal of Immunology.

[47]  Ilan Beer,et al.  Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor‐specific antigens , 2002, European journal of immunology.

[48]  S R Goldstein,et al.  Laser capture microdissection of single cells from complex tissues. , 1999, BioTechniques.

[49]  C. Paweletz,et al.  New approaches to proteomic analysis of breast cancer , 2001, Proteomics.

[50]  J. Neefjes,et al.  Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation , 1992, Nature.

[51]  Emil R. Unanue,et al.  Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation , 1990, Nature.

[52]  A. Vitiello,et al.  The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. , 1994, Journal of immunology.

[53]  W A Hendrickson,et al.  Crystal structure of I-Ak in complex with a dominant epitope of lysozyme. , 1998, Immunity.

[54]  S. Stevanović,et al.  Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens. , 2001, Journal of immunological methods.

[55]  J. Yewdell,et al.  Flanking sequences influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes , 1992, The Journal of experimental medicine.

[56]  D. Fremont,et al.  Structures of an MHC Class II Molecule with Covalently Bound Single Peptides , 1996, Science.

[57]  A. Agulnik,et al.  The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. , 1997, Immunity.

[58]  D. Suckau,et al.  Molecular epitope identification by limited proteolysis of an immobilized antigen-antibody complex and mass spectrometric peptide mapping. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[59]  M. Rechsteiner,et al.  The proteasome activator 11 S REG (PA28) and class I antigen presentation. , 2000, The Biochemical journal.

[60]  R A Houghten,et al.  Immunogenicity. I. Use of peptide libraries to identify epitopes that activate clonotypic CD4+ T cells and induce T cell responses to native peptide ligands. , 1999, Journal of immunology.

[61]  P. Kloetzel,et al.  The Interferon-γ-inducible 11 S Regulator (PA28) and the LMP2/LMP7 Subunits Govern the Peptide Production by the 20 S Proteasome in Vitro(*) , 1995, The Journal of Biological Chemistry.

[62]  J. Shabanowitz,et al.  An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins , 1996, The Journal of experimental medicine.

[63]  James McCluskey,et al.  Optimization of the MHC class I peptide cargo is dependent on tapasin. , 2002, Immunity.

[64]  P. Selby,et al.  Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis: evaluation of tissue preparation and sample limitations. , 2002, The American journal of pathology.

[65]  William S. Lane,et al.  Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size , 1992, Nature.

[66]  S. Kuhara,et al.  Differences in MHC class I self peptide repertoires among HLA-A2 subtypes. , 1995, Journal of immunology.

[67]  S. H. van der Burg,et al.  Induction of a primary human cytotoxic T‐lymphocyte response against a novel conserved epitope in a functional sequence of HIV‐1 reverse transcriptase , 1995, AIDS.

[68]  Hans-Georg Rammensee,et al.  Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells , 1990, Nature.

[69]  E. Kohn,et al.  Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer , 2002, Proteomics.

[70]  G. Butcher,et al.  Random Peptide Libraries , 2000 .

[71]  P. Cresswell,et al.  The thiol oxidoreductase ERp57 is a component of the MHC class I peptide-loading complex , 1998, Current Biology.

[72]  P. Cresswell,et al.  Disulfide bond isomerization and the assembly of MHC class I-peptide complexes. , 2002, Immunity.

[73]  Ulrich Steinhoff,et al.  Link between Organ-specific Antigen Processing by 20S Proteasomes and CD8+ T Cell–mediated Autoimmunity , 2002, The Journal of experimental medicine.

[74]  C. Creaser,et al.  Nano-electrospray and microbore liquid chromatography-ion trap mass spectrometry studies of copper complexation with MHC restricted peptides. , 2000, The Analyst.

[75]  Vladimir Brusic,et al.  Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network , 1998, Bioinform..

[76]  Ed van der Heeft,et al.  Autoreactivity against induced or upregulated abundant self-peptides in HLA-A*0201 following measles virus infection. , 2003, Human immunology.

[77]  P. A. Peterson,et al.  Retention of empty MHC class I molecules by tapasin is essential to reconstitute antigen presentation in invertebrate cells , 1999, The EMBO journal.

[78]  R. Henderson,et al.  Mass spectrometric analysis of peptides associated with the human class I MHC molecules HLA-A2.1 and HLA-B7 and identification of structural features that determine binding. , 1993, Chemical Immunology.

[79]  Jennifer N. Sutton,et al.  Competition Between Two MHC Binding Registers in a Single Peptide Processed from Myelin Basic Protein Influences Tolerance and Susceptibility to Autoimmunity , 2003, The Journal of experimental medicine.

[80]  J R Yates,et al.  Mass spectrometry. From genomics to proteomics. , 2000, Trends in genetics : TIG.

[81]  H. Orr,et al.  Mutations that impair a posttranscriptional step in expression of HLA-A and -B antigens. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[82]  Toni Aebischer,et al.  Immunoproteomics of Helicobacter pylori infection and relation to gastric disease , 2002, Proteomics.

[83]  Hans-Georg Rammensee,et al.  MHC Ligands and Peptide Motifs , 1998, Molecular Biology Intelligence Unit.

[84]  E. Petricoin,et al.  Evaluation of ethanol‐fixed, paraffin‐embedded tissues for proteomic applications , 2003, Proteomics.

[85]  Forest M. White,et al.  Immunodominance Among EBV-Derived Epitopes Restricted by HLA-B27 Does Not Correlate with Epitope Abundance in EBV-Transformed B-Lymphoblastoid Cell Lines1 , 2000, The Journal of Immunology.

[86]  J. Yewdell,et al.  Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. , 1999, Annual review of immunology.

[87]  D. Weber,et al.  HLA-DM and the MHC class II antigen presentation pathway , 1999, Immunologic research.

[88]  C. Slaughter,et al.  PA28, an activator of the 20 S proteasome, is inactivated by proteolytic modification at its carboxyl terminus. , 1993, The Journal of biological chemistry.

[89]  R. Henderson,et al.  Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes. , 1993, Journal of immunology.

[90]  J. Shabanowitz,et al.  Proteasomes can either generate or destroy MHC class I epitopes: evidence for nonproteasomal epitope generation in the cytosol. , 1998, Journal of immunology.

[91]  F. Momburg,et al.  HLA-DM, HLA-DO and tapasin: functional similarities and differences. , 2002, Current opinion in immunology.

[92]  Rosamonde E Banks,et al.  Use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis. , 2002, Methods in enzymology.

[93]  M. Lotze,et al.  Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. , 1993, Journal of immunology.

[94]  Hans-Georg Rammensee,et al.  MHC ligands and peptide motifs: first listing , 2004, Immunogenetics.

[95]  E. Petricoin,et al.  Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines , 2000, Electrophoresis.

[96]  A Sette,et al.  Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations. , 1994, Journal of immunology.

[97]  H. Grey,et al.  Isolation and characterization of naturally processed peptides bound by class II molecules and peptides presented by normal and mutant antigen-presenting cells. , 1993, Chemical Immunology.

[98]  L. K. Ely,et al.  Dissecting the role of peptides in the immune response: theory, practice and the application to vaccine design , 2003, Journal of peptide science : an official publication of the European Peptide Society.

[99]  Scott W. Reid,et al.  HLA Class I Binding Motifs Derived from Random Peptide Libraries Differ at the COOH Terminus from Those of Eluted Peptides , 1997, The Journal of experimental medicine.

[100]  J. Gorman,et al.  Determination of the disulfide bond arrangement of human respiratory syncytial virus attachment (G) protein by matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry , 1997, Protein science : a publication of the Protein Society.

[101]  A. Zijlstra,et al.  Targeting the proteome/epitome, implementation of subtractive immunization. , 2003, Biochemical and biophysical research communications.

[102]  P. Cresswell,et al.  Molecular Requirements for the Interaction of Class II Major Histocompatibility Complex Molecules and Invariant Chain with Calnexin (*) , 1995, The Journal of Biological Chemistry.

[103]  K. Tomer,et al.  Epitope mapping by mass spectrometry: determination of an epitope on HIV-1 IIIB p26 recognized by a monoclonal antibody. , 1996, Journal of immunology.

[104]  F Koning,et al.  Identification of a graft versus host disease-associated human minor histocompatibility antigen. , 1995, Science.

[105]  R Simon,et al.  Combinatorial Peptide Libraries and Biometric Score Matrices Permit the Quantitative Analysis of Specific and Degenerate Interactions Between Clonotypic TCR and MHC Peptide Ligands1 , 2001, The Journal of Immunology.

[106]  J. McCluskey,et al.  Avoidance of self-reactivity results in skewed CTL responses to rare components of synthetic immunogens. , 1998, Journal of immunology.

[107]  M. Lotze,et al.  Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[108]  D. Hunt,et al.  Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. , 1996, Journal of immunology.

[109]  J. Gorman,et al.  Characterization of pathotype-specific epitopes of newcastle disease virus fusion glycoproteins by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and post-source decay sequencing. , 1998, Journal of mass spectrometry : JMS.

[110]  C. Herberts,et al.  A single naturally processed measles virus peptide fully dominates the HLA‐A*0201‐associated peptide display and is mutated at its anchor position in persistent viral strains , 2000, European journal of immunology.

[111]  M. Mann,et al.  ER‐60, a chaperone with thiol‐dependent reductase activity involved in MHC class I assembly , 1998, The EMBO journal.

[112]  K. Tomer,et al.  Epitope mapping by a combination of epitope excision and MALDI-MS. , 2000, Methods in molecular biology.

[113]  C. Slaughter,et al.  PA28 activator protein forms regulatory caps on proteasome stacked rings. , 1994, Journal of molecular biology.

[114]  E. Pamer,et al.  Two Listeria monocytogenes CTL epitopes are processed from the same antigen with different efficiencies. , 1996, Journal of immunology.

[115]  P. Ricciardi-Castagnoli,et al.  Proteomic Analysis of Dendritic Cell-Derived Exosomes: A Secreted Subcellular Compartment Distinct from Apoptotic Vesicles1 , 2001, The Journal of Immunology.

[116]  P. Rovero,et al.  Differences in peptide-binding specificity of two ankylosing spondylitis-associated HLA-B27 subtypes , 2004, Immunogenetics.

[117]  H. Rammensee,et al.  Chemistry of peptides associated with MHC class I and class II molecules. , 1995, Current opinion in immunology.

[118]  W. Hildebrand,et al.  HLA-B15 peptide ligands are preferentially anchored at their C termini. , 1999, Journal of immunology.

[119]  K. Schwarz,et al.  Interferon-γ inducible exchanges of 20S proteasome active site subunits: Why? , 2001 .

[120]  A. Purcell,et al.  The use of post-source decay in matrix-assisted laser desorption/ionisation mass spectrometry to delineate T cell determinants. , 2001, Journal of immunological methods.

[121]  P. Cresswell,et al.  HLA-DM induces clip dissociation from MHC class II αβ dimers and facilitates peptide loading , 1995, Cell.

[122]  K. Tomer,et al.  Characterization of a discontinuous epitope of the human immunodeficiency virus (HIV) core protein p24 by epitope excision and differential chemical modification followed by mass spectrometric peptide mapping analysis , 2008, Protein science : a publication of the Protein Society.

[123]  P. A. Peterson,et al.  Crystal structures of two I-Ad-peptide complexes reveal that high affinity can be achieved without large anchor residues. , 1998, Immunity.

[124]  J. Yates,et al.  An automated multidimensional protein identification technology for shotgun proteomics. , 2001, Analytical chemistry.

[125]  J. Sidney,et al.  Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. , 1994, Molecular immunology.

[126]  T. Elliott,et al.  Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules. , 2000, Tissue antigens.

[127]  S. Stevanović,et al.  The use of HPLC-MS in T-cell epitope identification. , 2003, Methods.

[128]  C. Creaser,et al.  Electrospray mass spectrometry for the identification of MHC class I-associated peptides expressed on cancer cells. , 2002, Journal of immunological methods.

[129]  P. Cresswell,et al.  NK susceptibility varies inversely with target cell class I HLA antigen expression. , 1987, Journal of immunology.

[130]  R. Kennedy,et al.  Cutting Edge: Class I Presentation of Host Peptides Following HIV Infection1 , 2003, The Journal of Immunology.

[131]  A. Toubert,et al.  Differences in endogenous peptides presented by HLA-B*2705 and B*2703 allelic variants. Implications for susceptibility to spondylarthropathies. , 1996, The Journal of clinical investigation.

[132]  Forest M. White,et al.  Phosphorylated Peptides Are Naturally Processed and Presented by Major Histocompatibility Complex Class I Molecules in Vivo , 2000, The Journal of experimental medicine.

[133]  Hans-Georg Rammensee,et al.  Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules , 2004, Immunogenetics.

[134]  J. Trowsdale,et al.  Peptide Specificity of RT1-A1c, an Inhibitory Rat Major Histocompatibility Complex Class I Natural Killer Cell Ligand* , 2000, The Journal of Biological Chemistry.

[135]  William Arbuthnot Sir Lane,et al.  A subset of HLA-B27 molecules contains peptides much longer than nonamers. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[136]  J. Shabanowitz,et al.  Mass‐spectrometric evaluation of HLA‐A*0201‐associated peptides identifies dominant naturally processed forms of CTL epitopes from MART‐1 and gp100 , 1999 .

[137]  Kermit K. Murray,et al.  Laser capture microdissection MALDI for direct analysis of archival tissue. , 2003, Journal of proteome research.

[138]  Petricoin Ef rd,et al.  Cancer proteomics: from biomarker discovery to signal pathway profiling. , 2001, Cancer journal.

[139]  P. Matzinger,et al.  An innate sense of danger. , 1998, Seminars in immunology.

[140]  E. Unanue,et al.  Isolation and quantitation of a minor determinant of hen egg white lysozyme bound to I-Ak by using peptide-specific immunoaffinity. , 1998, Journal of immunology.

[141]  William Arbuthnot Sir Lane,et al.  Self-peptides bound to the type I diabetes associated class II MHC molecules HLA-DQ1 and HLA-DQ8. , 1994, International immunology.

[142]  A. Smolyar,et al.  The crystal structure of a T cell receptor in complex with peptide and MHC class II. , 1999, Science.

[143]  M. Tyers,et al.  From genomics to proteomics , 2003, Nature.

[144]  W. Hancock,et al.  An approach to the proteomic analysis of a breast cancer cell line (SKBR‐3) , 2003, Proteomics.

[145]  D. Feller,et al.  Identifying antigenic T-cell sites , 1991, Nature.

[146]  K. Anderson,et al.  Linking genomics to immunotherapy by reverse immunology--'immunomics' in the new millennium. , 2001, Current molecular medicine.

[147]  D. Pappin,et al.  The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis — Preliminary findings , 1999, Electrophoresis.

[148]  A. Rivett,et al.  Regulation of proteasome complexes by γ-interferon and phosphorylation , 2001 .

[149]  J. McCluskey,et al.  Identification of a dominant self‐ligand bound to three HLA B44 alleles and the preliminary crystallographic analysis of recombinant forms of each complex , 2002, FEBS letters.

[150]  R. Germain,et al.  Processing and Presentation of Endocytically Acquired Protein Antigens by MHC Class II and Class I Molecules , 1996, Immunological reviews.

[151]  J. Shabanowitz,et al.  The HA-2 Minor Histocompatibility Antigen Is Derived from a Diallelic Gene Encoding a Novel Human Class I Myosin Protein , 2001, The Journal of Immunology.

[152]  K Eichmann,et al.  The specificity of proteasomes: impact on MHC class I processing and presentation of antigens , 1999, Immunological reviews.

[153]  P. Cresswell,et al.  Thiol oxidation and reduction in major histocompatibility complex class I-restricted antigen processing and presentation. , 2002, Methods in enzymology.

[154]  P. Roholl,et al.  A measles virus glycoprotein-derived human CTL epitope is abundantly presented via the proteasomal-dependent MHC class I processing pathway. , 2001, The Journal of general virology.

[155]  R Kaufmann,et al.  Peptide sequencing by matrix-assisted laser-desorption mass spectrometry. , 1992, Rapid communications in mass spectrometry : RCM.

[156]  R. Banks,et al.  Laser capture microdissection and proteomics: Possibilities and limitation , 2001, Proteomics.

[157]  H. Grey,et al.  The minimal number of class II MHC-antigen complexes needed for T cell activation. , 1990, Science.

[158]  James McCluskey,et al.  A Naturally Selected Dimorphism within the HLA-B44 Supertype Alters Class I Structure, Peptide Repertoire, and T Cell Recognition , 2003, The Journal of experimental medicine.

[159]  D. Hunt,et al.  Conservation of minor histocompatibility antigens between human and non‐human primates , 1996, European Journal of Immunology.

[160]  Hans-Georg Rammensee,et al.  A role for the proteasome regulator PA28α in antigen presentation , 1996, Nature.

[161]  A. Vitiello,et al.  Impaired immunoproteasome assembly and immune responses in PA28-/- mice. , 1999, Science.

[162]  R. Henderson,et al.  Direct identification of an endogenous peptide recognized by multiple HLA-A2.1-specific cytotoxic T cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[163]  R. Henderson,et al.  HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. , 1992, Science.

[164]  J. Shabanowitz,et al.  Identification and modulation of a naturally processed T cell epitope from the diabetes-associated autoantigen human glutamic acid decarboxylase 65 (hGAD65). , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[165]  R A Houghten,et al.  Exploring immunological specificity using synthetic peptide combinatorial libraries. , 1999, Current opinion in immunology.

[166]  A. Vlahou,et al.  Proteomic approaches to biomarker discovery in prostate and bladder cancers , 2001, Proteomics.

[167]  T. Meyer,et al.  A Comparison of Murine and Human Immunoproteomes of Helicobacter pylori Validates the Preclinical Murine Infection Model for Antigen Screening , 2002, Infection and Immunity.

[168]  C. Herberts,et al.  A microcapillary column switching HPLC-electrospray ionization MS system for the direct identification of peptides presented by major histocompatibility complex class I molecules. , 1998, Analytical chemistry.

[169]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[170]  T. Elliott,et al.  The cell biology of MHC class I antigen presentation. , 2002, Tissue antigens.

[171]  R. Henderson,et al.  Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. , 1992, Science.

[172]  P. Cresswell,et al.  Regulation of MHC class I heterodimer stability and interaction with TAP by tapasin , 1997, Immunogenetics.

[173]  P. Jungblut,et al.  Proteome analysis of bacterial pathogens. , 2001, Microbes and infection.

[174]  E. Ballot,et al.  Identification of rat targets of anti-soluble liver antigen autoantibodies by serologic proteome analysis. , 2003, Clinical chemistry.

[175]  A. D. Jong Contribution of mass spectrometry to contemporary immunology. , 1998 .

[176]  C. Klade Proteomics approaches towards antigen discovery and vaccine development. , 2002, Current opinion in molecular therapeutics.

[177]  D. Glass,et al.  Polymorphism in the LMP2 gene influences disease susceptibility and severity in HLA-B27 associated juvenile rheumatoid arthritis. , 1996, The Journal of rheumatology.

[178]  J. Monaco,et al.  Identification of MECL-1 (LMP-10) as the third IFN-gamma-inducible proteasome subunit. , 1996, Journal of immunology.

[179]  P. Cresswell,et al.  The nature of the MHC class I peptide loading complex , 1999, Immunological reviews.

[180]  F. Momburg,et al.  Tapasin-the keystone of the loading complex optimizing peptide binding by MHC class I molecules in the endoplasmic reticulum. , 2002, Molecular immunology.

[181]  M. Luscher,et al.  Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis , 1991, Nature.

[182]  Karl-Heinz Wiesmüller,et al.  Peptide Vaccines and Peptide Libraries , 2001, Biological chemistry.

[183]  Yingdong Zhao,et al.  Toward synthetic combinatorial peptide libraries in positional scanning format (PS-SCL)-based identification of CD8+ Tumor-reactive T-Cell Ligands: a comparative analysis of PS-SCL recognition by a single tumor-reactive CD8+ cytolytic T-lymphocyte clone. , 2002, Cancer research.

[184]  S. Ceman,et al.  Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant. , 1992, Science.

[185]  R. Dwek,et al.  Recognition of carbohydrate by major histocompatibility complex class I- restricted, glycopeptide-specific cytotoxic T lymphocytes , 1994, The Journal of experimental medicine.

[186]  C. Watts,et al.  Capture and processing of exogenous antigens for presentation on MHC molecules. , 1997, Annual review of immunology.

[187]  P. Roepstorff,et al.  MHC class II loading of high or low affinity peptides directed by Ii/peptide fusion constructs: implications for T cell activation. , 2003, International immunology.

[188]  R. Henderson,et al.  Characteristics of endogenous peptides eluted from the class I MHC molecule HLA-B7 determined by mass spectrometry and computer modeling. , 1993, Journal of immunology.

[189]  Eilon Barnea,et al.  Tumor Antigens and Proteomics from the Point of View of the Major Histocompatibility Complex Peptides* , 2003, Molecular & Cellular Proteomics.

[190]  G. Hämmerling,et al.  Editing of the HLA‐DR‐peptide repertoire by HLA‐DM. , 1996, The EMBO journal.

[191]  P. Endert Genes regulating MHC class I processing of antigen , 1999 .

[192]  J. Vollmer,et al.  Characterization of processing requirements and metal cross‐reactivities in T cell clones from patients with allergic contact dermatitis to nickel , 1995, European journal of immunology.

[193]  H. Rammensee,et al.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.

[194]  N. Bulleid,et al.  The Role of ERp57 in Disulfide Bond Formation during the Assembly of Major Histocompatibility Complex Class I in a Synchronized Semipermeabilized Cell Translation System* , 2000, The Journal of Biological Chemistry.

[195]  D. Rognan,et al.  The same natural ligand is involved in allorecognition of multiple HLA-B27 subtypes by a single T cell clone: role of peptide and the MHC molecule in alloreactivity. , 1998, Journal of immunology.

[196]  S. Martin,et al.  Carrier‐reactive hapten‐specific cytotoxic T lymphocyte clones originate from a highly preselected T cell repertoire: implications for chemical‐induced self‐reactivity , 1995, European journal of immunology.

[197]  K. Wiesmüller,et al.  Analysis of peptide length preference of the rat MHC class Ia molecule RT1-A(u), by a modified random peptide library approach. , 2000, International immunology.

[198]  A Sette,et al.  Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. , 1992, Science.

[199]  K. Gevaert,et al.  Protein identification methods in proteomics , 2000, Electrophoresis.